# Molecular Docking and MD Modeling Techniques for the Development of Novel ROS1 Kinase Inhibitors

**Authors:** Mohammad Jahoor Alam, Arshad Jamal, Shaik Daria Hussain, Shahzaib Ahamad, Dinesh Gupta, Ashanul Haque

PMC · DOI: 10.3390/ph19020229 · Pharmaceuticals · 2026-01-28

## TL;DR

This study uses computational methods to identify new compounds that could inhibit a mutated ROS1 kinase linked to cancer drug resistance.

## Contribution

The novel contribution is the identification of four new drug candidates targeting the Gly2032Arg-mutated ROS1 kinase using in silico techniques.

## Key findings

- Four molecules (PubChem CIDs 67463531, 72544946, 139431449, and 139431487) showed high docking scores and drug likeness.
- MD simulations confirmed stability and binding affinity of the top compounds with the mutated ROS1 protein.
- DFT analysis provided insights into the molecular features of the identified compounds.

## Abstract

Background: Chemotherapy is a cornerstone of cancer treatment; however, resistance to first-line chemotherapeutic agents remains a major challenge. ROS1, one of fifty-eight receptor tyrosine kinases, has been implicated in various cancer subtypes, including glioblastoma, non-small-cell lung cancer, and cholangiocarcinoma. Notably, the Gly2032Arg mutation in the ROS1 protein has been linked to resistance against the kinase inhibitor crizotinib. Objectives: Given the challenge, we conducted a comprehensive in silico study to identify new drug candidates. Methods: The study starts with modeling the Gly2032Arg-mutated ROS1 protein, followed by structure-based screening of the PubChem database. Results: Out of 1760 molecules screened, we selected the top 4 molecules (PubChem CID: 67463531, 72544946, 139431449, and 139431487) with structural features similar to crizotinib, a high docking score, and drug likeness. To further validate the effectiveness of the identified compounds, we assessed their binding affinity using the Molecular Mechanics with Generalized Born Surface Area (MM-GBSA) scoring method. To underpin the behavior and stability of protein–ligand complexes, 500 ns molecular dynamics (MD) simulations were conducted, and parameters including RMSD, RMSF, and H-bond dynamics were studied and compared. Density functional theory (DFT) at the B3LYP/6-31G* level was performed to elucidate molecular features of the identified compounds. Conclusions: Overall, this study sheds light on a new series of compounds effective against mutated targets, thereby offering a new horizon in this area.

## Linked entities

- **Proteins:** ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase)
- **Chemicals:** crizotinib (PubChem CID 11597571)
- **Diseases:** glioblastoma (MONDO:0018177), non-small-cell lung cancer (MONDO:0005233), cholangiocarcinoma (MONDO:0019087)

## Full-text entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** cholangiocarcinoma (MESH:D018281), NSCLC (MESH:D002289), injury to (MESH:D014947), Cancer (MESH:D009369), lung cancer (MESH:D008175), XP (MESH:D014983), glioblastoma (MESH:D005909), deaths (MESH:D003643), metastasis (MESH:D009362), cytotoxicity (MESH:D064420), T (MESH:D001260)
- **Chemicals:** N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (MESH:C558660), aminopyridine (MESH:D000631), Spartan (MESH:C475571), thiazole (MESH:D013844), Water (MESH:D014867), Crizotinib (MESH:D000077547), indazole (MESH:D007191), salt (MESH:D012492), ceritinib (MESH:C586847), oxazole (MESH:D010080), ATP (MESH:D000255), triazole (MESH:D014230), piperidine (MESH:C032727), H (MESH:D006859), HOA (MESH:C072825), entrectinib (MESH:C000607349), lorlatinib (MESH:C000590786), sulfur (MESH:D013455), -fluorophenyl (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G1202R, Arg2032, Leu2026, L2026M, G595R, D2033N

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943418/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943418/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943418/full.md

---
Source: https://tomesphere.com/paper/PMC12943418